title: [Interferon-alpha-induced psychiatric side effects in patients with chronic viral hepatitis: a prospective, observational, controlled study].
abstract: OBJECTIVE
  Patients with chronic viral hepatitis suffer from a high prevalence of psychiatric problems. Furthermore, the treatment for chronic viral hepatitis, with interferon (IFN) alpha, induces the occurrence of further psychopathological symptoms. The authors examined whether patients with a pre-existing psychiatric diagnosis had more severe IFN alpha-induced psychiatric adverse effects, and whether they were more likely to interrupt the IFN alpha therapy, compared with control patients with no pre-existing psychiatric diagnosis. They also examined the psychopharmacological management of the interferon-alpha-induced psychiatric side effects.
  
  
  METHODS
  The authors studied prospectively 60 patients with chronic hepatitis B or C in Cagliari, Italy. Patients underwent psychiatric assessment before starting interferon alpha and monthly throughout the therapy.
  
  
  RESULTS
  After adjusting for the baseline psychopathology, there was no statistically significant difference in interferon-alpha-induced psychiatric adverse effects between patients with a pre-existing psychiatric diagnosis and controls. There was also no evidence that psychiatric cases were more likely than controls to interrupt the IFN alpha therapy because of psychiatric side effects. Moreover, there was no difference in the psychiatric adverse effects severe enough to require psychopharmacological treatment. Finally, psychopharmacological management successfully treated psychiatric symptoms induced by the IFN alpha.
  
  
  CONCLUSIONS
  Patients with a pre-existing psychiatric diagnosis do not have a specific vulnerability to interferon-alpha-induced psychiatric adverse effects.
authors.affiliation: Clinica Psichiatrica, Università degli Studi di Cagliari, Cagliari, Italy.
authors.forename: M Germana
authors.initials: MG
authors.lastname: Orrù
authors.forename: Antonella
authors.initials: A
authors.lastname: Baita
authors.forename: Rossella
authors.initials: R
authors.lastname: Sitzia
authors.forename: Alessandra
authors.initials: A
authors.lastname: Costa
authors.forename: Elisabetta
authors.initials: E
authors.lastname: Muntoni
authors.forename: Sabine
authors.initials: S
authors.lastname: Landau
authors.forename: Luchino
authors.initials: L
authors.lastname: Chessa
authors.forename: M Giulia
authors.initials: MG
authors.lastname: Farci
authors.forename: Bernardo
authors.initials: B
authors.lastname: Carpiniello
authors.forename: Carmine M
authors.initials: CM
authors.lastname: Pariante
mesh_terms: D000293:Adolescent; D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects*; D002908:Chronic Disease; D005260:Female; D006525:Hepatitis, Viral, Human / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000009:adverse effects*; D008297:Male; D001523:Mental Disorders / Q000150:complications*; D008875:Middle Aged; D019370:Observation; D011446:Prospective Studies
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha